Integrated Biopharma Inc's

• INBP's Stock Performance relative to its Competitors

Regeneron Pharmaceuticals Inc Share Performance -3.28% 30 Days

Regeneron Pharmaceuticals Inc Profile Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products. More about Regeneron Pharmaceuticals Inc 's Market Share

Allarity Therapeutics Inc Share Performance -20.77% This Quarter

Allarity Therapeutics Inc Profile Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles. More about Allarity Therapeutics Inc 's Market Share

Tiziana Life Sciences Ltd Share Performance -36.88% This Year

Tiziana Life Sciences Ltd Profile Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology. More about Tiziana Life Sciences Ltd's Market Share

Damora Therapeutics Inc Share Performance -32.02% 30 Days

Damora Therapeutics Inc Profile The company is a preclinical stage biotechnology firm focused on developing product candidates for various diseases. More about Damora Therapeutics Inc 's Market Share

Protagenic Therapeutics Inc new Share Performance -14.66% Over The Past 5 Days

Protagenic Therapeutics Inc new Profile Protagenic Therapeutics Inc has developed a novel business model focused on the discovery and development of novel therapeutics targeting the PGRMC1 receptor, which plays a crucial role in various diseases. By leveraging their proprietary technology and partnerships, the company aims to advance the development of innovative drugs that can effectively treat a range of conditions influenced by the PGRMC1 receptor. More about Protagenic Therapeutics Inc new's Market Share

Sources: Integrated Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 26, 2026 7:43 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Integrated Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.